Financial News

Nicox: First Half 2019 Financial Results and Business Update

  • H1 2019 net revenue1 of €5.6 million and net loss2 of €0.8 million
  • Enrollment completed in NCX 470 Phase 2 DOLOMITES clinical trial in patients with glaucoma or ocular hypertension. Top-line results on track for early Q4 2019
  • Collaboration in the Chinese market further strengthened with ZERVIATE and NCX 4251 transactions with Ocumension Therapeutics
  • Top-line results of NCX 4251 Phase 2 clinical trial on track for Q4 2019

Sophia Antipolis,

Read more

Nicox: Second Quarter 2019 Business Update and Financial Highlights

  • Enrollment completed in the NCX 470 Phase 2 clinical trial in patients with glaucoma and ocular hypertension with results expected in early Q4 of this year
  • Q2 2019 net revenue, including licensing payments, of €5.2 million

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided Q2 2019 operational highlights,

Read more

Nicox Announces Completion of Enrollment in NCX 470 Phase 2 Clinical Study with Top-Line Results on Track for Early 4Q 2019

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has completed enrollment of patients in its multicenter, United States (U.S.) Phase 2 clinical study evaluating NCX 470, a novel second generation nitric oxide (NO)-donating bimatoprost analog, being tested in patients with open-angle glaucoma or ocular hypertension for its ability to lower intraocular pressure (IOP).

Read more
More news
Press releases
More press releases